Central Cancer Registry Reporting Content IG
1.0.0 - STU 1 United States of America flag

This page is part of the Making EHR Data MOre available for Research and Public Health (MedMorph) Central Cancer Registry Reporting Content IG (v1.0.0: STU1) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

: Cancer Related Medication Administration - Example - JSON Representation

Raw json | Download


{
  "resourceType" : "MedicationAdministration",
  "id" : "cancer-related-medication-administration-example",
  "meta" : {
    "profile" : [
      🔗 "http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-related-medication-administration"
    ]
  },
  "text" : {
    "status" : "extensions",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Narrative</b></p><p><b>status:</b> completed</p><p><b>category:</b> Outpatient</p><p><b>medication:</b> rxnorm 1790099 doxorubicin hydrochloride 20 MG per 10 ML Injection</p><p><b>subject:</b> Amy Shaw</p><p><b>effective:</b> 2018-04-22</p><p><b>Performer:</b> Joseph Nichols</p><p><b>reasonReference:</b> Condition-primary-cancer-condition-breast</p><p><b>authoredOn:</b> 2018-04-12</p><p><b>note:</b> doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects.</p><p><b>Route:</b> SNOMED 47625008 Intravenous route (qualifier value)</p><p><b>Dose:</b> 105.96 mg</p></div>"
  },
  "status" : "completed",
  "category" : {
    "coding" : [
      {
        "system" : "http://terminology.hl7.org/CodeSystem/medication-admin-category",
        "code" : "outpatient"
      }
    ]
  },
  "medicationCodeableConcept" : {
    "coding" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "code" : "1790099",
        "display" : "10 ML doxorubicin hydrochloride 2 MG/ML Injection"
      }
    ]
  },
  "subject" : {
    🔗 "reference" : "Patient/example"
  },
  "effectiveDateTime" : "2018-04-22",
  "performer" : [
    {
      "actor" : {
        🔗 "reference" : "Practitioner/1"
      }
    }
  ],
  "reasonReference" : [
    {
      🔗 "reference" : "Condition/primary-cancer-condition-breast"
    }
  ],
  "note" : [
    {
      "authorReference" : {
        🔗 "reference" : "Practitioner/1"
      },
      "time" : "2018-04-22",
      "text" : "doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects."
    }
  ],
  "dosage" : {
    "route" : {
      "coding" : [
        {
          "system" : "http://snomed.info/sct",
          "code" : "47625008",
          "display" : "Intravenous route (qualifier value)"
        }
      ]
    },
    "dose" : {
      "value" : 105.96,
      "unit" : "mg",
      "system" : "http://unitsofmeasure.org",
      "code" : "mg"
    }
  }
}